ARK Genomic Revolution ETF (ARKG)
28.70
+0.42
(+1.49%)
USD |
BATS |
Mar 24, 16:00
28.70
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.75% | -0.07% | 1.916B | 2.240M |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0% | -- | -590.20M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | ARK ETF Trust |
| Prospectus Benchmark Index | |
| NASDAQ Health Care GR EUR | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Catherine Wood | 8.34 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
93
-590.20M
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 23, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 23, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Exact Sciences Corp | 11.59% | 66.27 | 1.31% |
| Schrodinger Inc Ordinary Shares | 5.47% | 25.55 | -0.31% |
| Pacific Biosciences of California Inc | 5.36% | 9.62 | 4.11% |
| Teladoc Health Inc | 5.05% | 25.04 | 3.32% |
| Ionis Pharmaceuticals Inc | 5.00% | 33.96 | 1.01% |
| Adaptive Biotechnologies Corp | 3.92% | 8.405 | 7.21% |
| Intellia Therapeutics Inc | 3.70% | 38.29 | 2.99% |
| Accolade Inc Ordinary Shares | 3.69% | 13.63 | 2.87% |
| CRISPR Therapeutics AG | 3.66% | 43.44 | 0.68% |
| Beam Therapeutics Inc | 3.48% | 30.41 | 0.23% |
News
Headline
Wire
Time (ET)
SA Breaking News
12/21 14:41
PR Newswire
12/19 17:22
SA Breaking News
10/31 09:04
SA Breaking News
04/29 14:30
SA Breaking News
03/18 13:00
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | ARK ETF Trust |
| Prospectus Benchmark Index | |
| NASDAQ Health Care GR EUR | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Catherine Wood | 8.34 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-24-23) | 0% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 22, 2023
Fund Details
| Key Dates | |
| Inception Date | 10/31/2014 |
| Last Annual Report Date | 7/31/2022 |
| Last Prospectus Date | 11/30/2022 |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
12/21 14:41
PR Newswire
12/19 17:22
SA Breaking News
10/31 09:04
SA Breaking News
04/29 14:30
SA Breaking News
03/18 13:00